# Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)

> **NCT01703286** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 42 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Placebo
- **DRUG:** Linagliptin
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT01703286
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2015-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01703286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01703286, "Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01703286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*